. 2017 Jul 3;20(2):169–175. doi: 10.1007/s12094-017-1706-2

Table 1.

Dose modification

Grade (NCI-CTCAE)^a	Recommended dose modification
Grade 1 or Grade 2 (tolerable)	Dose modification unnecessary
Grade 2 (intolerable) or Grade 3
1st appearance	Interrupt treatment until recovery to Grade 0 to 1 or baseline, then resume dosing at 720 mg bid^b
2nd appearance	Interrupt treatment until recovery to Grade 0 to 1 or baseline, then resume dosing at 480 mg bid^c
3rd appearance	Discontinue permanently
Grade 4
1st appearance	Discontinue permanently or, if it is preferable to continue treatment for a patient, interrupt treatment until recovery to Grade 0 to 1 or baseline, then resume dosing at 480 mg bid^c
2nd appearance	Discontinue permanently
Prolongation of QT interval
QTc >500 ms with >60 ms change from pre-treatment values	Discontinue permanently
QTc >500 ms with ≤60 ms change from pre-treatment values
1st appearance	Interrupt treatment until recovery to QTc ≤500 ms, then resume treatment at 720 mg bid^b
2nd appearance	Interrupt treatment until recovery to QTc ≤500 ms, then resume treatment at 480 mg bid^c
3rd appearance	Discontinue permanently

^aGraded by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v4.0

^bThe dose should be 480 mg if the dose was reduced to 720 mg before treatment interruption

^cTreatment should be discontinued permanently if the dose was reduced to 480 mg before treatment interruption